Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. It binds to THR-beta, predominantly found in liver tissues, and lowers triglyceride levels reducing potential progression of liver damage.
Resmetirom
Generic Name/API:Resmetirom
Packaging:30 capsules in a bottle, each capsule can be 60 mg, 80 mg, 100 mg.
Storage:Store at 20 °C to 25°C (68 °F to 77°F).
Dosage:For dosage information, please check the General Information section.
Strength:Capsules of 60 mg, 80 mg or 100 mg each.
Indication:Resmetirom is the first and only FDA approved drug to be approved for treatment of nonalcoholic steatohepatitis (NASH) in adults who have moderate to advanced fibrosis (consistent with stage F2 to F3 fibrosis). However, use of resmetirom is to be avoided in patients with decompensated liver cirrhosis. Since it targets liver scarring, improving fibrosis in 25% or 1 in 4 patients- offering hope for patients with progressive liver disease due to overnutrition, obesity or metabolic issues.
Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. It binds to THR-beta, predominantly found in liver tissues, and lowers triglyceride levels reducing potential progression of liver damage. Due to increase in fat accumulation in the liver, NASH or noncirrhotic nonalcoholic steatohepatitis can progress to cirrhosis due to inflammation and fibrotic changes. It is indicated to be used in conjunction with diet and exercise for the treatment of adults with (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
STRENGTH:
Capsules of 60 mg, 80 mg or 100 mg each.
DOSAGE:
The recommended resmetirom dosage depends on actual body weight.
- For patients weighing <100 kg, the recommended dosage is 80 mg orally once daily.
- For patients weighing ≥100 kg, the recommended dosage is 100 mg orally once daily.
Administer resmetirom with or without food.
- Dosage modifications may be required in patients who are under treatment with moderate CYP2C8 inhibitors.
- Concomitant use of REZDIFFRA with strong CYP2C8 inhibitors (e.g., gemfibrozil) is not recommended due to drug interactions that may result in increased risk of adverse reactions.
- If REZDIFFRA is used concomitantly with a moderate CYP2C8 inhibitor (e.g., clopidogrel) , reduce the dosage of REZDIFFRA:
- <100 kg, reduce the dosage of REZDIFFRA to 60 mg once daily.
- ≥100 kg, reduce the dosage of REZDIFFRA to 80 mg once daily.
SIDE EFFECTS:
Side effects of resmetirom use include:
- Hepatotoxicity
- Gallbladder-Related Adverse Reactions
STORAGE:
Store at 20 °C to 25°C (68 °F to 77°F); excursions permitted to 15 °C to 30°C (59° F to 86°F).
- Hepatotoxicity: Hepatotoxicity has been reported in patients who use resmetirom. In the case of one patient who was being administered resmetirom, elevations in liver enzymes as well as immunoglobulin G levels, suggesting drug-induced autoimmune-like hepatitis (DI-ALH), was observed. The liver tests returned to baseline following hospitalization and discontinuation of REZDIFFRA without any therapeutic intervention. Monitor patients on resmetirom for liver test elevations and signs of hepatotoxicity (e.g., fatigue, nausea, RUQ pain, jaundice, fever, rash, eosinophilia >5%).
If hepatotoxicity occurs, discontinue treatment and monitor. If labs normalize, assess the risk-benefit of restarting. If not, evaluate for DI-ALH or autoimmune liver disease. - Gallbladder-Related Adverse Reactions: Resmetirom-treated patients experienced higher rates of cholelithiasis, acute cholecystitis, and gallstone-related pancreatitis than placebo. If suspected, perform appropriate gallbladder related diagnostic and clinical evaluations. Interrupt treatment, if an acute gallbladder event occurs, until resolution of symptoms.
- Drug Interaction with Certain Statins: Co-administration of REZDIFFRA increases exposure to atorvastatin, pravastatin, rosuvastatin, and simvastatin, increasing the risk of associated side effects. Adjust statin dosage as needed and monitor for liver enzyme elevations, myopathy, or rhabdomyolysis.
FAQ
What is resmetirom used for?
Resmetirom is used to treat nonalcoholic steatohepatitis (NASH) in adults who have moderate to advanced fibrosis, but avoided for patients with decompensated liver cirrhosis.
What are the common side effects of resmetirom use?
Hepatotoxicity and gallbladder-related adverse reactions are the most common side effects of resmetirom use.
Can rezdiffra be used in specific populations i.e. for pregnant, breastfeeding , pediatric and geriatric use?
There is no data on resmetirom use during pregnancy or breastfeeding, including its presence in milk or effects on infants. Use in elderly patients is linked to higher rates of adverse reactions, and it has not been studied in those with severe renal impairment or cirrhosis. Resmetirom should be avoided in patients with decompensated cirrhosis (Child-Pugh B or C). Risks associated with maternal NASH, such as gestational diabetes and preterm birth, should be considered when prescribing.
What is the cost of rezdiffra (resmetirom) in India?
The cost of rezdiffra (resmetirom) in India varies since it is not locally approved and requires legal import. Pricing depends on supplier availability, international currency fluctuations, and import charges. For the most accurate cost details, contact 24/7QualityMeds at +91 9967979080.
How to buy rezdiffra (resmetirom) online in India?
To buy rezdiffra (resmetirom) online in India at a genuine price, reach out to 24/7QualityMeds. We support patients with legal medicine import, verify prescriptions, source from trusted suppliers, and ensure safe doorstep delivery across India.
What are the key criteria for selecting a supplier?
While selecting a supplier, we essentially ensure that the supplier holds a valid Good Distribution Practice (GDP) certificate and possesses a valid operating license. These credentials confirm that the suppliers adherence to International standards for the proper distribution of medicinal product.
